CME/CE

In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related analyses. The discussion highlights considerations for early initiation, use in combination with SGLT2 inhibitors, patient selection, dosing and monitoring, and management of potassium and renal function changes in clinical practice.

In this Patient-Clinician Connection, Dr. Sayna Norouzi discusses shared decision-making approaches for adult patients with C3 glomerulonephritis (C3GN) receiving complement-targeted therapies. Through a clinical patient vignette, Dr. Norouzi demonstrates patient-centered communication techniques for discussing mechanisms, treatment considerations, and long-term kidney preservation goals in clear, accessible language. Dr. Norouzi reviews key differences among treatment approaches, including mechanism of action, proteinuria reduction, kidney function stabilization, monitoring requirements, route of administration, adherence considerations, and infection risk. The activity also highlights the importance of vaccination review, ongoing monitoring, and aligning treatment decisions with patient priorities and lifestyle factors to support collaborative care planning and patient engagement in C3GN management.

Updated diabetes guidelines now recognize a new “other” category of diabetes linked to excess cortisol. This classification reflects emerging prevalence data showing that hypercortisolism may play a much larger role in diabetes development than previously understood. Let’s explore what these new guidelines mean and how they could influence clinical practice.

Did you miss our symposium at ESC HF 2026? It’s not too late! This CME-accredited broadcast replay focuses on improving the diagnosis and management of obstructive hypertrophic cardiomyopathy (oHCM). Learn how to distinguish oHCM from heart failure and how cardiac myosin inhibitors can optimize patient outcomes. Join us and gain valuable tips on applying these insights in practice.

For more information please visit the Heart Failure Congress 2026 website.

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.